Research programme: biotherapeutic proteins - Promosome

Drug Profile

Research programme: biotherapeutic proteins - Promosome

Latest Information Update: 14 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Promosome
  • Class Anticoagulants; Biological proteins; Proteins
  • Mechanism of Action Enzyme replacements; RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Alpha 1-antitrypsin deficiency; Haemophilia; Lysosomal storage diseases; Metabolic disorders

Most Recent Events

  • 14 Sep 2016 mRNA engineering technologies developed at the Scripps Research Institute licensed to Promosome world-wide, before September 2016 (Promosome website, September 2016)
  • 01 Jan 2016 Early research in Metabolic disorders, Lysosomal storage diseases, Haemophilia and Alpha 1-antitrypsin deficiency in USA (Parenteral) (Promosome pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top